Clinical Trial Update: Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a phase 1/phase 2 study of Hu3F8 in combination with GM-CSF for relapsed/refractory high-risk neuroblastoma, currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Hu3F8 (Hu3F8)
• sargramostim (sargramostim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING